摘要
目的 探讨介入治疗联合膀胱灌注丝裂霉素C(MMC)预防浅表性膀胱癌术后复发的临床价值。 方法 2 8例浅表性膀胱癌患者局部手术后随机分为二组 ,每组 14例。分别采用介入治疗加膀胱灌注MMC和MMC单纯膀胱灌注治疗。 结果 2 8例随访 12～ 2 6个月 ,平均 2 1个月。介入加灌注组肿瘤复发 1例 ,单纯MMC灌注组肿瘤复发 4例 ,两组肿瘤复发率差异有显著性意义 (P <0 .0 5 )。 结论 介入治疗联合膀胱灌注MMC预防浅表性膀胱癌术后复发疗效较好 ,副反应少 。
Objective To study the therapeutic efficacy of combined interventional chemotherapy and intravesical instillation of mitomycin on preventing bladder cancers from recurring after local ablation. Methods 28 patients with superficial bladder cancers were randomized into combined interventional chemotherapy and intravesical instillation of mitomycin or intravesical instillation of mitomycin alone for preventing recurrence after local ablation.The result was assessed by χ 2 test. Results The patients have been followed up for 12～26 months (mean 21 months).1 case has had tumor recurrence in the combined modality therapy group and 4 in the intravesical instillation alone group,the tumor recurrence rate being 7% (1/14) and 29% (4/14) respectively(P<0.05). Conclusions Combined use of interventional chemotherapy and intravesical instillation of mitomycin is effective in preventing superficial bladder cancer from recurring after local ablation with fewer adverse effects.The ragimen is not only reliable but also safe.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2003年第2期104-105,共2页
Chinese Journal of Urology
